Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Association Between Childhood Obesity and Myopia: A Prospective Cohort Study

18. November 2026 aktualisiert von: Weina Liu, Southeast University, China

This prospective observational cohort study will examine the association between obesity and myopia in children and adolescents. Approximately 600 participants aged 6 to 18 years will be enrolled at the Fourth Affiliated Hospital of Nanjing Medical University, including 300 participants with obesity and 300 participants with a body mass index within the normal range.

Participants will not be assigned to any study intervention. The study will collect information from body measurements, body composition assessments, eye examinations, lifestyle questionnaires, follow-up assessments, and existing clinical records. The investigators will evaluate whether obesity-related measures, including body mass index, body mass index z-score, body fat percentage, and visceral fat, are associated with myopia, axial length, refractive status, and changes in these outcomes over time. Lifestyle factors such as outdoor activity, near work, screen use, sleep, and diet will also be considered.

Studienübersicht

Status

Rekrutierung

Intervention / Behandlung

Detaillierte Beschreibung

This is a single-center, prospective, observational cohort study involving children and adolescents aged 6 to 18 years who attend the pediatric outpatient clinic of the Fourth Affiliated Hospital of Nanjing Medical University. Approximately 600 participants will be enrolled, including 300 participants with obesity and 300 participants with a body mass index within the normal range. Obesity will be defined according to the Chinese screening standard for overweight and obesity among school-aged children and adolescents (WS/T 586-2018).

No randomization, masking, or study-related clinical intervention will be performed. At baseline, the study will collect anthropometric measurements, body composition data, ophthalmic examination results, and lifestyle questionnaire data. Planned follow-up assessments will be used to evaluate changes in refractive status, axial length, scleral thickness, and myopia progression.

The principal study outcomes include myopia status and changes in axial length, spherical equivalent refraction, scleral thickness, and myopia progression. The study will examine associations between these outcomes and obesity-related measures, including body mass index, body mass index z-score, body fat percentage, and visceral fat.

Information on age, sex, parental history of myopia, birth history, medical history, medication use, outdoor activity, near work, screen use, sleep, and diet will be collected as potential confounding factors. Existing clinical laboratory results obtained during routine medical care, including blood lipids, fasting blood glucose, fasting insulin, C-peptide, and glycated hemoglobin, may be included in exploratory analyses when available.

The study will not collect additional blood, stool, or other biological samples solely for research purposes and will not increase the frequency or volume of blood collection. If residual blood remaining after routine clinical testing is available and its use is permitted by the ethics approval and informed consent, it may be used for related laboratory measurements without additional blood collection. The absence of existing laboratory results or residual blood will not affect study eligibility.

Statistical analyses will include group comparisons, multivariable linear or logistic regression, and linear mixed-effects models for repeated follow-up measurements. Analyses will adjust for relevant demographic, familial, and lifestyle factors.

Studientyp

Beobachtungs

Einschreibung (Geschätzt)

600

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienkontakt

Studienorte

    • Jiangsu
      • Nanjing, Jiangsu, China
        • Rekrutierung
        • The Fourth Affiliated Hospital of Nanjing Medical University
        • Kontakt:

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

6 Jahre bis 18 Jahre (Kind, Erwachsene)

Akzeptiert gesunde Freiwillige

Ja

Studienberechtigte Geschlechter

Alle

Probenahmeverfahren

Nicht-Wahrscheinlichkeitsprobe

Studienpopulation

The study population will consist of approximately 600 children and adolescents aged 6 to 18 years attending the pediatric outpatient clinic of the Fourth Affiliated Hospital of Nanjing Medical University. Potential participants will be identified through the pediatric outpatient system and referrals from outpatient physicians. Approximately 300 participants will be enrolled in the obesity cohort and 300 in the normal-BMI cohort according to WS/T 586-2018. Enrollment requires written informed consent from a legal guardian and assent from the child or adolescent, as applicable.

Beschreibung

Inclusion Criteria:

  • Aged 6 to 18 years and able to cooperate with anthropometric measurements, ophthalmic examinations, questionnaire assessments, and follow-up visits.
  • For the obesity cohort, body mass index meets the definition of obesity in the Chinese screening standard for overweight and obesity among school-aged children and adolescents (WS/T 586-2018); for the normal-BMI cohort, body mass index is within the normal range.
  • Best-corrected visual acuity of at least 0.8 in both eyes, with no apparent strabismus, opacity of the refractive media, or ocular structural abnormality.
  • The participant and legal guardian understand the study, voluntarily sign the applicable informed consent and assent documents, and are expected to comply with study procedures.
  • Able to complete the questionnaires and planned follow-up assessments.

Exclusion Criteria:

  • An ocular disease that may affect visual acuity or measurement of refractive status, including cataract, glaucoma, fundus disease, apparent strabismus, or another ocular structural abnormality.
  • A severe systemic disease or neurodevelopmental disorder that prevents cooperation with study examinations or follow-up.
  • A secondary condition or factor that substantially affects growth, development, or assessment of body weight.
  • Recent receipt of a myopia-control intervention that may substantially affect the evaluation of myopia progression when complete information about the intervention cannot be obtained.
  • Poor anticipated adherence, inability to complete follow-up, or withdrawal of informed consent by the legal guardian.

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Beobachtungsmodelle: COHORT
  • Zeitperspektiven: PROSPECTIVE

Kohorten und Interventionen

Gruppe / Kohorte
Intervention / Behandlung
Obesity Cohort

Approximately 300 children and adolescents aged 6 to 18 years whose body mass index meets the definition of obesity in the Chinese screening standard for overweight and obesity among school-aged children and adolescents (WS/T 586-2018). Participants will undergo observational assessments only and will not be assigned to a study intervention.

The program should emphasize the health consequences of obesity and evidence-based weight management strategies, including maintaining a balanced diet, controlling energy intake, increasing physical activity, reducing sedentary behavior and screen time, and ensuring adequate sleep. Instruction, individualized counseling, and family involvement should be incorporated to improve health awareness and self-management skills and facilitate the development of a healthy lifestyle.

Normal-BMI Cohort

Approximately 300 children and adolescents aged 6 to 18 years whose body mass index is within the normal range according to the Chinese screening standard for overweight and obesity among school-aged children and adolescents (WS/T 586-2018). Participants will undergo observational assessments only and will not be assigned to a study intervention.

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Change From Baseline in Axial Length
Zeitfenster: Baseline and 24 months

Axial length will be measured in millimeters for each eye using the same non-contact optical biometer at baseline and follow-up. Change in axial length (ΔAL) will be calculated as the value at 24 months minus the baseline value. Positive values indicate axial elongation. Changes will be compared between children and adolescents with obesity and those with normal weight. Associations of BMI, BMI-for-age Z score, body fat percentage, and visceral fat level with ΔAL will also be evaluated.

Baseline and 24 months
Change From Baseline in Spherical Equivalent Refractive Error
Zeitfenster: Baseline and 24 months

Spherical equivalent refractive error will be calculated for each eye as spherical power plus one-half of cylindrical power and expressed in diopters (D), based on cycloplegic autorefraction. Change in spherical equivalent refractive error (ΔSE) will be calculated as the value at 24 months minus the baseline value. A negative change indicates a myopic shift. Changes will be compared between children and adolescents with obesity and those with normal weight. Associations of BMI, BMI-for-age Z score, body fat percentage, and visceral fat level with ΔSE will also be evaluated.

Baseline and 24 months

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Change From Baseline in Scleral Thickness
Zeitfenster: Baseline and 24 months

Scleral thickness will be measured in micrometers at the same predefined anatomical location using optical coherence tomography at baseline and follow-up. Change in scleral thickness (ΔST) will be calculated as the value at 24 months minus the baseline value. A negative change indicates scleral thinning. Changes will be compared between children and adolescents with obesity and those with normal weight.

Baseline and 24 months
Change From Baseline in Regional Choroidal Thickness at 24 Months
Zeitfenster: Baseline and 24 months

Intraocular pressure, corneal curvature radius, mean keratometry, central corneal thickness, and anterior chamber depth will be measured in both eyes using the same standardized ophthalmic instruments at baseline and at the 24-month follow-up. Changes will be calculated as the 24-month value minus the corresponding baseline value. Intraocular pressure will be expressed in mmHg, corneal curvature radius and anterior chamber depth in millimeters, mean keratometry in diopters, and central corneal thickness in micrometers. Each parameter will be analyzed and reported separately.

Baseline and 24 months
Change From Baseline in Regional Retinal Thickness at 24 Months
Zeitfenster: Baseline and 24 months

Retinal thickness will be measured in micrometers at predefined temporal, central foveal, and nasal locations in both eyes using optical coherence tomography. Change at each location will be calculated as the value at 24 months minus the corresponding baseline value. Measurements from the temporal, central foveal, and nasal locations will be analyzed and reported separately.

Baseline and 24 months
Change From Baseline in Fasting Lipid Profile at 24 Months
Zeitfenster: Baseline and 24 months

Fasting lipid profile will include total cholesterol, triglycerides, high-density lipoprotein cholesterol, and low-density lipoprotein cholesterol, all expressed in mmol/L. Laboratory results obtained during routine clinical care will be collected at baseline and at 24 months when available. Change in each lipid parameter will be calculated as the 24-month value minus the corresponding baseline value. Each lipid parameter will be analyzed and reported separately. No additional blood sampling will be performed solely for this study.

Baseline and 24 months
Body Fat Percentage
Zeitfenster: Baseline and 24 months

Body fat percentage will be estimated using bioelectrical impedance analysis and expressed as a percentage of total body mass.

Baseline and 24 months
Body Fat Mass
Zeitfenster: Baseline and 24 months

Fat mass will be estimated using bioelectrical impedance analysis and expressed in kilograms (kg).

Baseline and 24 months
Body Muscle Mass
Zeitfenster: Baseline and 24 months

Muscle mass will be estimated using bioelectrical impedance analysis and expressed in kilograms (kg).

Baseline and 24 months
Total Body Water
Zeitfenster: Baseline and 24 months

Total body water will be estimated using bioelectrical impedance analysis and expressed in liters (L).

Baseline and 24 months
Change From Baseline in Fasting Plasma Glucose at 24 Months
Zeitfenster: Baseline and 24 months

Change in fasting plasma glucose will be calculated as the 24-month value minus the baseline value and expressed in mmol/L.

Baseline and 24 months
Change From Baseline in Fasting Insulin at 24 Months
Zeitfenster: Baseline and 24 months

Change in fasting insulin will be calculated as the 24-month value minus the baseline value and expressed in µIU/mL.

Baseline and 24 months
Change From Baseline in C-Peptide at 24 Months
Zeitfenster: Baseline and 24 months

Change in C-peptide concentration will be calculated as the 24-month value minus the baseline value and expressed in pmol/L.

Baseline and 24 months
Change From Baseline in Hemoglobin A1c (HbA1c) at 24 Months
Zeitfenster: Baseline and 24 months

Change in hemoglobin A1c (HbA1c) will be calculated by subtracting the baseline HbA1c percentage from the 24-month HbA1c percentage. The change will be expressed in percentage points.

Baseline and 24 months
Change From Baseline in Homeostasis Model Assessment of Insulin Resistance (HOMA-IR) at 24 Months
Zeitfenster: Baseline and 24 months

At each visit, HOMA-IR will be calculated as fasting plasma glucose (mmol/L) multiplied by fasting insulin (µIU/mL), divided by 22.5, when both measurements are available from the same visit. Change will be calculated as the 24-month HOMA-IR value minus the baseline HOMA-IR value. HOMA-IR is a unitless index.

Baseline and 24 months

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Publikationen und hilfreiche Links

Die Bereitstellung dieser Publikationen erfolgt freiwillig durch die für die Eingabe von Informationen über die Studie verantwortliche Person. Diese können sich auf alles beziehen, was mit dem Studium zu tun hat.

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Tatsächlich)

5. Juli 2025

Primärer Abschluss (Geschätzt)

1. Juli 2027

Studienabschluss (Geschätzt)

1. Juli 2027

Studienanmeldedaten

Zuerst eingereicht

14. November 2026

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

18. November 2026

Zuerst gepostet (Tatsächlich)

20. November 2026

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

20. November 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

18. November 2026

Zuletzt verifiziert

1. Juli 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

NEIN

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Nein

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .

Abonnieren